242 related articles for article (PubMed ID: 19906626)
1. Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.
Rathbun CR; Liedtke MD; Blevins SM; Harrison D; Lockhart SM; Salvaggio M; Acosta EP
HIV Clin Trials; 2009; 10(5):328-36. PubMed ID: 19906626
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
3. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
[TBL] [Abstract][Full Text] [Related]
4. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A
AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Mallolas J; Podzamczer D; Milinkovic A; Domingo P; Clotet B; Ribera E; Gutiérrez F; Knobel H; Cosin J; Ferrer E; Arranz JA; Roca V; Vidal F; Murillas J; Pich J; Pedrol E; Llibre JM; Dalmau D; García I; Aranda M; Cruceta A; Martínez E; Blanco JL; Lazzari Ed; Gatell JM;
J Acquir Immune Defic Syndr; 2009 May; 51(1):29-36. PubMed ID: 19390327
[TBL] [Abstract][Full Text] [Related]
7. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Slish J; Ma Q; Zingman BS; Reichman RC; Fischl MA; Gripshover B; Forrest A; Brazeau D; Boston NS; Catanzaro L; DiFrancesco R; Morse GD
Ther Drug Monit; 2007 Oct; 29(5):560-5. PubMed ID: 17898644
[TBL] [Abstract][Full Text] [Related]
8. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
9. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Foglia E; Bonfanti P; Rizzardini G; Bonizzoni E; Restelli U; Ricci E; Porazzi E; Scolari F; Croce D
PLoS One; 2013; 8(2):e57777. PubMed ID: 23460905
[TBL] [Abstract][Full Text] [Related]
11. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
12. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
13. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
14. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
[TBL] [Abstract][Full Text] [Related]
15. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.
Higgins N; Zingman BS; Slish J; Reichman RC; Fischl MA; Gripshover B; Tooley K; Boston N; Forrest A; Brazeau D; Catanzaro LM; DiFrancesco R; Lliguicota F; Ma Q; Morse GD
Am J Addict; 2007; 16(6):488-94. PubMed ID: 18058416
[TBL] [Abstract][Full Text] [Related]
17. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Stanley TL; Joy T; Hadigan CM; Liebau JG; Makimura H; Chen CY; Thomas BJ; Weise SB; Robbins GK; Grinspoon SK
AIDS; 2009 Jul; 23(11):1349-57. PubMed ID: 19474651
[TBL] [Abstract][Full Text] [Related]
18. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
[TBL] [Abstract][Full Text] [Related]
19. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
20. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Ferrer E; del Rio L; Martínez E; Curto J; Domingo P; Ribera E; Negredo E; Rosales J; Saumoy M; Ordóñez J; Gatell JM; Podzamczer D
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1061-5. PubMed ID: 21166602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
